Key result
Control of chronic inflammation and management of traditional risk factors are essential to reduce the elevated cardiovascular risk in patients with rheumatoid arthritis.
This review proposes a practical approach for assessing and managing cardiovascular risk in patients with rheumatoid arthritis, addressing a gap in specific randomized clinical trial data.
Answers are grounded in this paper and cite their sources.
CV risk management in RA lacks dedicated RCT guidance; leaves open optimal prevention strategies for clinicians and researchers.
Cardiovascular (CV) comorbidities are a frequent extra-articular manifestation of rheumatoid arthritis (RA). Cardiovascular disease (CVD) with accelerated atherosclerosis is a major cause of morbidity and mortality in patients with RA. Subclinical CVD may be present since the early phase of RA. Not only traditional but also non-traditional CV risk factors are involved in the pathogenesis of RA-related CVD. Due to the lack of specifically designed randomized clinical trials, it is still unclear which tools to use to perform CV risk assessment, how to interpret the results and which interventions are appropriate in RA patients both to prevent and to manage CVD. Based on the available evidence, we propose a practical approach.
No takes yet. Share an insight, caveat, or question.
Gualtierotti et al. (2017) conducted a review in Rheumatoid arthritis with cardiovascular comorbidities. Cardiovascular risk management was evaluated. Control of chronic inflammation and management of traditional risk factors are essential to reduce the elevated cardiovascular risk in patients with rheumatoid arthritis.
Synapse has enriched 10 related papers. Consider them for comparative context: